183 related articles for article (PubMed ID: 30371744)
1. The latest treatment options for bladder cancer.
Crabb SJ; Douglas J
Br Med Bull; 2018 Dec; 128(1):85-95. PubMed ID: 30371744
[TBL] [Abstract][Full Text] [Related]
2. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
Alfred Witjes J; Lebret T; Compérat EM; Cowan NC; De Santis M; Bruins HM; Hernández V; Espinós EL; Dunn J; Rouanne M; Neuzillet Y; Veskimäe E; van der Heijden AG; Gakis G; Ribal MJ
Eur Urol; 2017 Mar; 71(3):462-475. PubMed ID: 27375033
[TBL] [Abstract][Full Text] [Related]
3. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
4. Can bladder preservation therapy come to the center stage?
Inamoto T; Ibuki N; Komura K; Juri H; Yamamoto K; Yamamoto K; Fujita K; Nonomura N; Narumi Y; Azuma H
Int J Urol; 2018 Feb; 25(2):134-140. PubMed ID: 29171098
[TBL] [Abstract][Full Text] [Related]
5. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in the management of bladder cancer: Introduction.
Smith AB
Urol Oncol; 2018 Mar; 36(3):95-96. PubMed ID: 29158137
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients.
Miyata Y; Nomata K; Ohba K; Matsuo T; Hayashi N; Sakamoto I; Uetani M; Sakai H
Eur J Surg Oncol; 2015 Mar; 41(3):361-7. PubMed ID: 25312685
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer: overview and management. Part 2: muscle-invasive and metastatic bladder cancer.
Anderson B
Br J Nurs; 2018 Oct; 27(18):S8-S20. PubMed ID: 30281356
[TBL] [Abstract][Full Text] [Related]
9. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder. A metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy.
Montie JE
J Urol; 2005 Nov; 174(5):1783-4. PubMed ID: 16217285
[No Abstract] [Full Text] [Related]
10. Recent developments in the treatment of advanced bladder cancer.
Godwin JL; Hoffman-Censits J; Plimack E
Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
[TBL] [Abstract][Full Text] [Related]
11. [Chemoradiotherapy for muscle-invasive cancer: methods, surveillance and results. An update from the cancer committee of the French National Association of Urology].
Quintens H; Roupret M; Larré S; Neuzillet Y; Pignot G; Compérat E; Wallerand H; Houédé N; Roy C; Soulié M; Pfister C;
Prog Urol; 2012 Jan; 22(1):13-6. PubMed ID: 22196000
[TBL] [Abstract][Full Text] [Related]
12. [Neoadjuvant therapy before radical cystectomy for muscle-invasive bladder cancer].
Rexer H; Merseburger A
Urologe A; 2016 Oct; 55(10):1366-1367. PubMed ID: 27637180
[No Abstract] [Full Text] [Related]
13. [Classification and treatment of bladder cancer].
Orv Hetil; 1986 Mar; 127(11):651. PubMed ID: 3960518
[No Abstract] [Full Text] [Related]
14. Novel therapeutics in the treatment of bladder cancer.
Shah JB; McKiernan JM
Curr Opin Urol; 2004 Sep; 14(5):287-93. PubMed ID: 15300149
[TBL] [Abstract][Full Text] [Related]
15. Bladder cancer.
Gwynn ES; Clark PE
Curr Opin Oncol; 2006 May; 18(3):277-83. PubMed ID: 16552241
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and clinical outcomes of patients with node-positive muscle-invasive bladder cancer.
Bruins HM; Stein JP
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1091-101. PubMed ID: 18588454
[TBL] [Abstract][Full Text] [Related]
17. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
Zhang M; Tao R; Zhang C; Shen Z
Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377
[TBL] [Abstract][Full Text] [Related]
18. [Conservative treatment of locally advanced bladder carcinoma: neoadjuvant chemotherapy, TUR and radiotherapy. Results in 40 patients].
Serretta V; Vasile P; Falletta V; Piazza F; Pavone C; Pavone-Macaluso M
Arch Ital Urol Androl; 1998 Jun; 70(3 Suppl):37-40. PubMed ID: 9707769
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
20. Selection of treatment for muscle infiltrating transitional cell bladder cancer.
Whitmore WF
Arch Esp Urol; 1990; 43 Suppl 2():219-22. PubMed ID: 2096783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
